期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分化型甲状腺癌的^131I治疗：需要新思维和新方法 被引量：8

原文传递
导出
摘要 早在20世纪40年代初，国外学者就开始采用放射性碘治疗甲状腺疾病，其中Seidlin等采用放射性碘成功消除了甲状腺癌转移灶为很有影响的研究报道。国内在20世纪60年代起开始应用放射性碘治疗甲状腺癌，经过多年的临床实践，^131I治疗分化型甲状腺癌（DTC）已发展成对该病术后后续治疗的首选治疗或经典治疗方法。有关^131I治疗DTC的方法学及疗效分析方面的研究已有大量文献报道。
作者 陆汉魁
机构地区 上海交通大学附属第六人民医院核医学科
出处 《中华核医学杂志》 CAS CSCD 北大核心 2009年第3期145-146,共2页 Chinese Journal of Nuclear Medicine
关键词 ^131I治疗 分化型甲状腺癌 放射性碘治疗 甲状腺癌转移灶 思维 甲状腺疾病 国外学者 临床实践
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献11

  • 1Beierwaltes WH.The history of the use of radioactive iodine.Semin Nucl Med,1979,9:151-155.
  • 2Sawka AM,Thephamongkhol K,Brouwers M,et al.A systematic review and meta analysis of the effectiveness of radiative iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metsb,2004,89:3668-3676.
  • 3Sweeney DC,Johnston GS.Radioiodine therapy of thyroid cancer.Endocrinol Metab Clin North Am,1995,24:803-839.
  • 4傅宏亮,王辉,吴靖川,李佳宁,邹仁健,杜学亮.影响分化型甲状腺癌术后^131I清甲治疗疗效的因素分析[J].中华核医学杂志,2009,29(3):149-152. 被引量：35
  • 5陈泽泉,罗全勇,陈立波,丁颖,余永利,陆汉魁,朱瑞森.儿童及青少年分化型甲状腺癌的临床特征及^131I治疗分析[J].中华核医学杂志,2009,29(3):153-155. 被引量：10
  • 6高再荣,常伟,崔坤炜,曹卫,曹国祥,黄代娟,张永学.甲状腺乳头状癌术后刺激状态Tg预测^131I清甲治疗后Tg水平的价值[J].中华核医学杂志,2009,29(3):156-159. 被引量：21
  • 7Chung JK.Sodium iodide symporter:its role in nuclear medicine.J Nucl Med,2002,43:1188-1200.
  • 8Wang JB,Kaplan MM,Meyer KB,et al.Ablative radioactive iodine therapy for apparently localized thyroid carcinoma:a decision analytic perspective.Endocrinol Metab Clin North Am,1990,19:741-760.
  • 9McClellan DR,Francis GL.Thyroid cancer in children,pregnant women,and patients with Grave's disease.Endocrinol Metab Clin North Am,1996,25:27-48.
  • 10Kloos RT.Approach to the patient with a positive serum thyruglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer.J Clin Endocrinol Metab,2008,93:1519-1525.

二级参考文献28

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006.CA Cancer J Clin,2006,56:106-130.
  • 2Sawka AM,Thephamongkhol K,Brouwers M,et al.A systematic review and Meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metab,2004,89:3668-3676.
  • 3Hackshaw A,Harmer C,Mallick U,et al.131Ⅰ activity for remnant ablation in patients with differentied thyroid cancer:a systematic review.J Clin Endocrinol Metab,2007,92:28-38.
  • 4Pacini F,Molinaro E,Castagna MG,et al.Ablation of thyroid residues with 30 mCi 131^I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.J Clin Endocrinol Metab,2002,87:4063-4068.
  • 5Doi SAR,Woodhouse NJ,Thalib L,et al.Ablation of the thyroid remnant and 131^I dose in differentiated thyroid cancer:a Meta-analysis revisited.Clin Med Res,2007,5:87-90.
  • 6Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007.CA Cancer J Clin,2007,57:43-66.
  • 7Miccoli P,Minuto MN,Ugolini C,et al.Papillary thyroid cancer:pathological parameters as prognostic factors in different classes of age.Otolaryngol Head Neck Surg,2008,138:200-203.
  • 8Newman KD.The current management of thyroid tumors in childhood.Semin Pediatr Surg,1993,2:69-74.
  • 9Parisi MT,Mankoff D.Differentiated pediatric thyroid cancer:correlates with adult disease,controversies in treatment.Semin Nucl Med,2007,37:340-356.
  • 10Yamashita S,Saenko V.Mechanisms of disease:molecular genetics of childhood thyroid cancers.Nat Clin Praet Endocrinol Metab,2007,3:422-429.

共引文献56

同被引文献88

  • 1陈立波,罗全勇,余永利,金常青,于建芳,陆汉魁,朱瑞森,沈艳.分化型甲状腺癌患者的^(131)I-SPECT/CT断层融合显像[J].中国医学影像技术,2004,20(7):1111-1113. 被引量：11
  • 2朱瑞森,余永利,陆汉魁,罗全勇,陈立波.分化型甲状腺癌术后^(131)I治疗的必要性[J].上海交通大学学报（医学版）,2006,26(9):1042-1043. 被引量：20
  • 3余永利,罗全勇,陈立波,罗琼,丁颖,陆汉魁,朱瑞森,马寄晓.分化型甲状腺癌术后~131Ⅰ治疗生存率分析[J].中华核医学杂志,2006,26(5):261-263. 被引量：21
  • 4赵劼,孙辉,温强,高识,马庆杰.分化型甲状腺癌术后首次^(131)I清除剩余甲状腺组织的效果及影响因素[J].中国老年学杂志,2006,26(11):1460-1461. 被引量：1
  • 5李映兰.护理心理学[M].北京:人民卫生出版,2007:124.
  • 6Liu B,Kuang A,Huang R,et al.Influence of vitamin C on salivary absorbed dose of ^131I in thyroid cancer patients:a prospective,randomized,single-blind,controlled trial.J Nucl Med,2010,51:618-623.
  • 7Grewal RK,Larson SM,Pentlow CE,et al.Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.J Nucl Med,2009,50:1605-1610.
  • 8Jentzen W,Balschuweit D,Schmitz J,et al.The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET/CT imaging.Eur J Nucl Med Mol Imaging,2010,37:2298-2306.
  • 9Aung W,Murata Y,Ishida R,et al.Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjgren′s syndrome.J Nucl Med,2001,42:38-43.
  • 10Jentzen W,Hobbs RF,Stahl A,et al.Pre-therapeutic 124I PET/CT dosimetry confirms low average absorbed doses per administered ^131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.Eur J Nucl Med Mol Imaging,2010,37:884-895.

引证文献8

二级引证文献36

中华核医学杂志
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部